{"@context":"https://schema.org","@graph":[{"@id":"https://thehippiescientist.net/compounds/tb-500/#entity","@type":["ChemicalSubstance","MolecularEntity"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"evidence tier","value":"Preliminary evidence"},{"@type":"PropertyValue","propertyID":"evidence label","value":"D"},{"@type":"PropertyValue","propertyID":"AI entity completeness score","value":34}],"category":"Synthetic thymosin beta-4 fragment","description":"TB-500 is a synthetic fragment of thymosin beta-4 marketed for muscle recovery and connective-tissue repair; the underlying Tβ4 biology has real scientific grounding, but the synthetic fragment sold as TB-500 has thin direct human evidence and an unresolved FDA compounding status pending July 2026 PCAC review.","identifier":[{"@type":"PropertyValue","propertyID":"THS entity id","value":"ths:compound:tb-500"},{"@type":"PropertyValue","propertyID":"THS slug","value":"tb-500"}],"mentions":[{"@id":"https://thehippiescientist.net/compounds/bpc-157/#entity","@type":["ChemicalSubstance","Thing"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"relationship type","value":"related-to"}],"name":"BPC 157","url":"https://thehippiescientist.net/compounds/bpc-157/"}],"name":"TB-500","subjectOf":{"@id":"https://thehippiescientist.net/compounds/tb-500/#evidence-data"},"url":"https://thehippiescientist.net/compounds/tb-500/"},{"@id":"https://thehippiescientist.net/compounds/tb-500/#evidence-data","@type":"Article","about":{"@id":"https://thehippiescientist.net/compounds/tb-500/#entity"},"author":{"@type":"Person","name":"Willie B. Randolph III","url":"https://thehippiescientist.net/info/author/","@id":"https://thehippiescientist.net/info/author/#person","affiliation":{"@id":"https://thehippiescientist.net/#organization"}},"dateModified":"2026-06-30","dateReviewed":"2026-06-30","description":"TB-500 is a synthetic fragment of thymosin beta-4 marketed for muscle recovery and connective-tissue repair; the underlying Tβ4 biology has real scientific grounding, but the synthetic fragment sold as TB-500 has thin direct human evidence and an unresolved FDA compounding status pending July 2026 PCAC review.","headline":"TB-500 evidence, safety, and entity data","mainEntity":{"@id":"https://thehippiescientist.net/compounds/tb-500/#entity"},"mentions":[{"@id":"https://thehippiescientist.net/compounds/bpc-157/#entity","@type":["ChemicalSubstance","Thing"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"relationship type","value":"related-to"}],"name":"BPC 157","url":"https://thehippiescientist.net/compounds/bpc-157/"}],"publisher":{"@type":"Organization","name":"The Hippie Scientist","url":"https://thehippiescientist.net","@id":"https://thehippiescientist.net/#organization"},"url":"https://thehippiescientist.net/compounds/tb-500/"}]}